Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 177Lu-IM-3050
177Lu-3050 · 1 trial · 1 indication
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 6.0, including adverse events (SAEs), AEs leading to discontinuation, and deaths
Type, frequency, seriousness, and severity of AEs graded using the NCI-CTCAE criteria version 6.0, including SAEs, AEs leading to discontinuation, and deaths
| Arm | Type | Description |
|---|---|---|
| Dose Escalation: 177Lu-IM-3050 | EXPERIMENTAL | 177Lu-IM-3050 administered intravenously on a 6-week cycle |
| Dose Expansion: 177Lu-IM-3050 | EXPERIMENTAL | 177Lu-IM-3050 administered intravenously on a 6-week cycle |
| Name | Type | Description |
|---|---|---|
| 177Lu-IM-3050 | DRUG | 177Lu-IM-3050 is a FAP-directed radiopharmaceutical |
Inclusion Criteria: * ≥18 years of age * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1 or 2 * Histological or cytological diagnosis of a solid tumor * Participants must be refractory to or have relapsed after at least one prior standard therapeutic regimen. Participants mu...
177Lu-3050 is an investigational small molecule being developed for the treatment of solid malignancies. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities. The drug is being studied in patients with advanced cancer to evaluate its safety and efficacy.
The specific molecular target of 177Lu-3050 has not been disclosed. As a small molecule, it is designed to interact with cellular components involved in cancer growth, but the exact target is not publicly available. The drug is being studied in solid malignancies, where it may act on pathways relevant to tumor progression.
177Lu-3050 is being developed by Immunome, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IMNM. The company is conducting clinical trials to evaluate the drug's potential in treating advanced solid tumors. Immunome is responsible for the drug's development and regulatory strategy.
177Lu-3050 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory body. The ongoing Phase 1 trial is designed to assess the drug's safety, tolerability, and preliminary efficacy in patients with advanced solid malignancies.
177Lu-3050 is being studied in a single Phase 1 clinical trial with the identifier NCT07505771. This trial, titled 'A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer,' is currently recruiting participants in the United States. The study aims to enroll 105 patients aged 18 years and older with solid malignancies.
Yes, 177Lu-3050 is also known as 177Lu-IM-3050. Both names refer to the same investigational drug being developed by Immunome, Inc. The alternative name is used in clinical trial documentation, such as the Phase 1 study NCT07505771, which is evaluating the drug in patients with advanced solid tumors.